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BACKGROUND: This study provides the latest available relative survival data for Australian childhood cancer patients.
METHODS: Data from the population-based Australian Paediatric Cancer Registry were used to describe relative survival outcomes
using the period method for 11903 children diagnosed with cancer between 1983 and 2006 and prevalent at any time between
1997 and 2006.
RESULTS: The overall relative survival was 90.4% after 1 year, 79.5% after 5 years and 74.7% after 20 years. Where information onstage
at diagnosis was available (lymphomas, neuroblastoma, renal tumours and rhabdomyosarcomas), survival was significantly poorer for
more-advanced stage. Survival was lower among infants compared with other children for those diagnosed with leukaemia, tumours
of the central nervous system and renal tumours but higher for neuroblastoma. Recent improvements in overall childhood cancer
survival over time are mainly because of improvements among leukaemia patients.
CONCLUSION: The high and improving survival prognosis for children diagnosed with cancer in Australia is consistent with various
international estimates. However, a 5-year survival estimate of 79% still means that many children who are diagnosed with cancer will
die within 5 years, whereas others have long-term health morbidities and complications associated with their treatments. It is hoped
that continued developments in treatment protocols will result in further improvements in survival.
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More than 600 children between 0–14 years of age are diagnosed
with cancer each year in Australia corresponding to an age-
standardised incidence rate (2000 World Standard) of 157 cases/
million children per year (Baade et al, 2010). This incidence rate is
among the highest reported internationally (Steliarova-Foucher
et al, 2005a; Stack et al, 2007; Li et al, 2008; Linabery and Ross,
2008; Ocheni et al, 2008; Spix et al, 2008; Swaminathan et al, 2008),
consistent with the strong positive association between country-
specific childhood-cancer incidence rates and affluence (Howard
et al, 2008). Although the Australian childhood cancer incidence
rate represents less than 1% of all invasive cancers diagnosed in
this country, it is still the most common cause of disease-related
death for children between 1–14 years of age in Australia
(Australian Institute of Health and Welfare, 2009). Many survivors
face significant long-term adverse health effects because of the
cancer itself or as a result of treatment (Aziz et al, 2006; Goldsby
et al, 2006; Kurt et al, 2008; Landier and Bhatia, 2008; Oeffinger
et al, 2008). The diagnosis of cancer in a child also has a
considerable and ongoing impact, both psychological and
financial, on the families concerned (Cohn et al, 2003; Hardy
et al, 2008).
Advances in therapy for childhood cancer, including the
introduction of multiagent chemotherapy and multimodal therapy,
combined with greater understanding of the molecular basis of
childhood cancers, have led to widespread improvements in survival
for childhood cancer in developed nations. (Zuccolo et al, 2006;
Ellison et al, 2007; Anonymous, 2009; Perme and Jereb, 2009).
Ongoing population-based survival studies are essential for
providing robust indicators to monitor the availability of effective
treatments and healthcare provision for cancer patients, and to
compare the cancer burden between countries (Gatta et al, 2002;
Desandes et al, 2008). Although some survival estimates for
childhood cancers have been published recently for Australia
(AIHW and AACR, 2008), the use of the standard site-based
ICD-0-3 classification has limited comparisons with international
estimates that use the current morphology-based standard for
coding childhood cancer, the third edition of the International
Classification of Childhood Cancers (ICCC-3) (Steliarova-Foucher
et al, 2005b).
This paper reports the latest available population-based
survival estimates for children diagnosed with cancer in Australia
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scategorised by the ICCC-3 diagnostic groupings, enabling for the
first time comparability with population-based estimates from
other countries.
MATERIALS AND METHODS
Australian paediatric cancer registry
The Australian Paediatric Cancer Registry (APCR) is one of the few
population-based national registries of childhood cancer in the
world. Established in 1977, it obtained full coverage of all
Australian states and Territories from 1983, and currently includes
cases upto 31st December 2006. Notification of invasive cancer is
a statutory requirement for all public and private hospitals and
pathology services in Australia, and so the survival data reported
here are considered to represent all eligible Australian children
between 0–14 years of age diagnosed with invasive cancer.
Confirmation and validation of cancer records are achieved
through site visits by the APCR Data Manager to the major
children’s hospitals around Australia, when patients’ charts are
reviewed and additional information on clinical characteristics and
treatment are extracted. Since 1983, 95.3% of diagnostic records in
the APCR were based on histological verification (74.0% histology
of primary, 0.3% histology of metastasis, 20.7% on cytology or
Haematology and 0.4% on autopsy with histology) (Baade et al,
2010). Of the remainder, most were clinical investigations (3.9% of
total). Less than 0.2% of diagnoses were based on death certificate
only.
Although tumours of benign or uncertain behaviour are gene-
rally not reported for adults, the ICCC-3 includes non-malignant
intracranial and intraspinal tumours in diagnostic groups III
(tumours of the central nervous system) and X (germ cell tumours –
see Table 1) (Steliarova-Foucher et al, 2005b). Therefore,
throughout this paper, childhood cancers refer to all malignant
neoplasms as well as intracranial and intraspinal tumours of
benign or uncertain behaviour. Survival results are reported here
by ICCC-3 diagnostic groups, with additional results provided for
diagnostic subgroups where numbers were sufficient for mean-
ingful interpretation.
Mortality status
Follow-up for mortality status upto the 31st December 2006 was
performed through record linkage between the APCR database
and the Australian National Death Index. The record linkage,
using deterministic and probabilistic algorithms, was undertaken
by staff at the Australian Institute of Health and Welfare.
Relative survival
Relative survival was used to approximate disease-specific survival
because it does not rely on accurate cause of death coding
(Dickman et al, 2004). It was calculated from the observed
probability of all-cause survival among childhood cancer patients
divided by the expected probability of survival within the corres-
ponding Australian population stratified by age, sex and calendar
year. Relative survival estimates were calculated using actuarial
techniques based on the period methodology (Brenner et al, 2004).
The period method has been shown through validation studies to
be particularly useful in monitoring childhood cancer survival and
provides more timely estimates of survival than the cohort method
(Brenner et al, 2007; Steliarova-Foucher et al, 2007).
Using the period method, cancer patients were considered ‘at
risk’ of mortality if they constituted a prevalent case for at least
some time during the 10-year period from 1st January 1997 to 31st
December 2006. The survival times of patients who were not
Table 1 Relative survival for Australian children diagnosed with cancer by diagnostic group, 1997–2006
a
Relative survival (95% confidence intervals)
Diagnostic group N
b 1 year 5 year 20 year
All cancers 11903 90.6 (89.8–91.3) 79.6 (78.5–80.6) 74.8 (73.7–76.0)
I. Leukaemias 3833 92.8 (91.6–93.8) 80.6 (78.8–82.2) 75.9 (73.9–77.8)
IA Lymphoid leukaemias 3121 96.3 (95.3–97.1) 85.0 (83.1–86.7) 79.7 (77.5–81.7)
IB Acute myeloid leukaemias 537 79.2 (74.5–83.2) 63.4 (57.9–68.4) 62.3 (56.7–67.5)
II. Lymphomas 1220 93.5 (91.3–95.2) 89.8 (87.1–92.0) 88.0 (84.8–90.6)
IIA. Hodgkin lymphomas 500 98.8 (96.4–99.6) 97.7 (94.7–99.0) 95.4 (91.4–97.8)
IIB. Non-Hodgkin lymphomas (excl. Burkitt lymphoma) 486 90.2 (85.4–93.4) 81.7 (76.0–86.1) 79.5 (73.2–84.6)
IIC. Burkitt lymphoma 206 90.3 (83.5–94.4) 90.4 (83.6–94.4) 91.2 (84.3–95.3)
III. Tumours of the CNS
c 2562 82.6 (80.5–84.5) 71.0 (68.5–73.3) 64.4 (61.6–67.0)
IIIA. Ependymomas and choroid plexus tumours 242 88.8 (81.8–93.2) 69.3 (60.6–76.4) 62.2 (53.2–69.9)
IIIB. Astrocytomas 1266 87.3 (84.4–89.6) 78.8 (75.5–81.8) 71.7 (67.6–75.4)
IIIC. Intracranial & intraspinal embryonal tumours 437 70.0 (64.1–75.1) 48.7 (42.6–54.5) 41.7 (35.5–47.7)
IIID. Other gliomas 267 65.2 (57.4–71.9) 55.1 (47.1–62.3) 48.9 (40.6–56.7)
IV. Neuroblastoma 650 87.8 (84.0–90.8) 67.8 (62.7–72.4) 64.2 (58.7–69.1)
V. Retinoblastoma 348 99.6 (95.6–100.0) 98.4 (94.5–99.7) 97.8 (92.8–99.7)
VI. Renal tumours 683 95.5 (92.7–97.3) 88.6 (84.6–91.6) 86.9 (82.5–90.4)
VII. Hepatic tumours 153 85.5 (76.7–91.2) 76.0 (66.0–83.4) 74.4 (63.8–82.4)
VIII. Malignant bone tumours 494 93.6 (89.6–96.0) 68.9 (62.8–74.2) 64.1 (57.7–69.8)
IX. Soft tissue sarcomas 693 90.6 (87.0–93.3) 72.1 (67.0–76.6) 65.2 (59.8–70.1)
IXA. Rhabdomyosarcomas 343 92.8 (87.6–95.9) 71.7 (63.9–78.2) 65.3 (57.2–72.2)
X. Germ cell tumors
c 467 92.2 (88.0–95.0) 89.4 (84.7–92.7) 85.0 (79.2–89.3)
XI. Other malignant epithelial neoplasms & melanomas 776 96.8 (94.2–98.2) 93.3 (90.1–95.5) 86.5 (81.4–90.3)
XID. Malignant melanomas 493 99.0 (96.1–99.8) 97.5 (94.3–99.0) 91.1 (84.7–95.0)
XII. Other & unspecified 24 77.4 (45.1–92.2) 72.2 (41.7–88.7) 58.3 (29.4–79.0)
aIncludes all children who were diagnosed between January 1st 1983 and December 31st 2006, and were ‘at risk’ at some point between 1997 and 2006 (inclusive).
bN represents the total number at risk between 1997 and 2006 (inclusive).
cIncludes cancers of benign or uncertain behaviour.
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sknown to have died before 31st December 2006 were censored at
that date. The Ederer II method (Ederer et al, 1961) was used to
calculate expected survival. Cases diagnosed on the basis of death
certificate only (n¼21, 0.15%) and autopsy with histology (n¼82,
0.58%) were excluded from the survival analysis.
Stage (specific cancers only)
Information about the spread of disease at diagnosis was collected
through patients’ clinical records for the following diagnostic
groups: lymphomas, neuroblastoma, renal tumours and rhabdo-
myosarcomas (a subgroup of soft-tissue sarcomas). The specific
classification systems used for categorising stage for each of the
diagnostic group/subgroup were: Hodgkin lymphoma – Ann Arbor
classification system; (Carbone et al, 1971) Non-Hodgkin lympho-
mas (including Burkitt lymphoma) – Murphy classification
system; (Murphy et al, 1989) Neuroblastoma – International
Neuroblastoma Staging System; (Brodeur et al, 1993) Renal
tumours – Third National Wilms’ Tumor Study; (D’Angio et al,
1989) and Rhabdomyosarcomas – Intergroup Rhabdomyosarcoma
Study-I. (Maurer et al, 1988) Although there was stage information
collected for some cases of retinoblastoma, the low proportion of
these cancers with stage information (B33%) was not sufficient
to report. Due to small numbers, the staging categories for
rhabdomyosarcomas were collapsed to I/II and III/IV for analysis.
Generally, Stage I tumours are localised to the part of the body
where the cancer originated without any evidence of spread and
were able to be surgically removed. Stage II tumours are similar,
except that the tumour has been incompletely removed. Stage III
tumours have greater regional involvement, preventing surgical
resection and often including involvement of lymph nodes. Finally
Stage IV tumours are when the cancer has spread (metastasised) to
distant parts of the body, such as the lungs or bone marrow.
Poisson models
Generalised linear models with a Poisson error structure were used
to model the excess mortality (upto 5 years after diagnosis)
associated with a diagnosis of childhood cancer for all cases
combined and within each diagnostic group, including the effects
of age group, sex, grouped year of diagnosis and, where relevant,
stage at diagnosis. We were only able to apply the Poisson models
to the diagnostic subgroups of lymphoid leukaemias (IA), acute
myeloid leukaemias (IB) and rhabdomyosarcomas (IXA) because
of instability and lack of convergence in the models for the other
cancer subgroups.
RESULTS
Description of cohort
A total of 11903 children between 0–14 years of age who were
diagnosed with cancer in Australia between 1983 and 2006 were ‘at
risk’ between 1997 and 2006, with a median follow-up time of 8.9
years (range 0–24 years). Of these children, 5% (n¼565) had died
within 1 year, and 11% (n¼1266) within 5 years of diagnosis. The
most common cancers were leukaemias (32%, with 81% of these
being lymphoid leukaemias), tumours of the central nervous
system (CNS, 22%) and lymphomas (10%), which in combination
represented nearly two-thirds (64%) of all cases.
1- and 5-year relative survival
The relative survival for all children diagnosed with cancer was
91% (95% CI¼90–91%) after 1 year and 80% (79–81) after
5 years (Table 1). Among the diagnostic groups, 5-year survival
was highest for retinoblastoma (98%; (95–100)), other malig-
nant epithelial neoplasms and melanomas (93%; (90–96)) and
lymphomas (90%; (87–92)). The diagnostic groups with the
poorest survival outcomes after 5 years were neuroblastoma
(68%; (63–72)), malignant bone tumours (69%; (63–74)) and
tumours of the CNS (71%; (69–73)). Five-year survival for lymphoid
leukaemias (85%; (83–87)) was substantially higher than that for
acute myeloid leukaemias (63%; (58–68)). Among lymphomas,
5-year survival was better for Hodgkin lymphomas (98%; (95–99))
than for either Burkitt lymphoma (90%; (84–94)) or other non-
Hodgkin lymphomas (82%; (76–86)). Among children diagnosed
with cancers of the CNS, 5-year survival for those diagnosed with
astrocytomas (79%; (76–82)) was higher than for intracranial and
intraspinal embryonal tumours (49%; (43–55)).
Survival by stage at diagnosis
When children diagnosed with lymphomas, neuroblastoma, renal
tumours and rhabdomyosarcomas were considered together
(n¼2896), there were 23% stage I, 17% stage II, 25% stage III
and 19% stage IV cases, whereas 16% of these cancers had
unknown stage (Table 2).
Of the cancers for which stage data were available, survival was
significantly worse within each diagnostic group for children
with more advanced stage at diagnosis (Tables 2 and 3).
The largest difference in survival by stage occurred for children
with neuroblastoma, where 5-year relative survival was 96%
(86–99) for stage I disease compared with 49% (42–56) for stage
IV disease. Although the association with stage was significant
for renal tumours, the survival differential was limited to stage IV
disease (Table 3).
Survival by sex
After adjustment for age-group, year of diagnosis and (where
relevant) stage, the only diagnostic group for which there was a
significant sex differential in relative survival was leukaemias,
where girls were significantly less likely (HR¼0.76; (0.62–0.93),
P¼0.007) than boys to die within 5 years of diagnosis (Table 3).
When leukaemias were analysed separately by subgroup, the sex
differential was significant for lymphoid leukaemias (HR¼0.65;
(0.50–0.85), P¼0.002), but not for myeloid leukaemias
(HR¼1.04; (0.72–1.49), P¼0.840).
Survival by age-group
For those cancers for which there was a significant age differential
in survival outcomes (after adjusting for sex, year of diagnosis and,
where relevant, stage), survival was generally poorer for very
young cancer patients (infants diagnosed at less than 1 year), and
also, to a lesser extent, for older children (5 years and over)
compared with children between 1–4 years of age at diagnosis
(Table 3). The significant age differential in survival for all
childhood cancers combined (P¼0.002) was largely because of the
poorer survival among infants (HR¼1.39; (1.2–1.7), P¼0.001).
When analysed by diagnostic group, there was a poorer prognosis
among infants for all leukaemias combined (Po0.001). This
was particularly evident for lymphoid leukaemias (Po0.001),
whereas the age effect was not significant for myeloid leukaemias
(P¼0.123). In addition, infants had poorer survival for tumours of
the CNS (Po0.001) and renal tumours (Po0.05); however, infants
had significantly better survival for neuroblastoma (Po0.001).
Older children also had poorer survival for all leukaemias
combined relative to the 1–4 year age-group (Po0.001), which
was again limited to lymphoid leukaemias (Po0.001), as well as
hepatic tumours (Po0.05), malignant bone tumours (Po0.05) and
the subgroup of rhabdomyosarcomas (Po0.05). In contrast,
children between 10–14 years of age had improved survival for
tumours of the CNS compared with children between 1–4 years of
age (Po0.001).
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sSurvival by period of diagnosis
The prognosis for all childhood cancers combined improved by
grouped year of diagnosis (Table 3), with overall 5-year relative
survival of 77% (76–79) for children diagnosed in 1992–1998
increasing to 81% (80–82) for children diagnosed in 1999–2006
(HR¼0.84; (0.74–0.94), P¼0.003). This improvement in survival
was particularly evident among children diagnosed with leukae-
mias (75 vs 84%, respectively; HR¼0.59; (0.48–0.73), Po0.001),
and this change was consistent for both lymphoid leukaemias and
myeloid leukaemias. Consistent changes were observed among
boys and girls, with no evidence (P40.10) of interaction between
sex and time period (results not shown). There was some
suggestion, although not quite reaching statistical significance,
of an improvement in survival for lymphomas (86% (80–91) vs
91% (87–93), respectively; HR¼0.61; (0.36–1.04), P¼0.07058).
Similar patterns were seen for several of the other diagnostic
groups, but none of the remaining hazards ratios, including that
for all cancers combined excluding leukaemia, were statistically
significant (P40.05).
Long-term survival
Long-term survival curves by diagnostic group and stage are
shown in Figures 1 and 2, respectively. Overall 20-year relative
survival for all children diagnosed with cancer was 75% (74–76)
(Table 1). Retinoblastoma (98%; (93–100)), lymphomas (88%;
(85–91)) and renal tumours (87%; (83–90)) were the diagnostic
groups with the best long-term prognoses. Of the lymphomas,
Hodgkin lymphomas (95%; (91–98)) and Burkitt lymphoma (91%;
(84–95)) had better long-term survival than other non-Hodgkin
lymphomas (80%; (73–85)). Cancers with the poorest long-term
survival were malignant bone tumours (64%; (58–70)), tumours of
the CNS (64%; (62–67)) and neuroblastoma (64%; (59–69)).
As in the analysis of survival by stage, longer-term survival
remained consistently poorer among children with more advanced
cancers for each of the diagnostic groups/subgroups shown in
Figure 2. However, irrespective of stage, the survival rates generally
stabilised within the first few years following diagnosis.
DISCUSSION
This paper reports the latest survival information for Australian
children diagnosed with cancer between 0–14 years of age, using a
population-based paediatric cancer registry and the current
international classification for childhood cancers. Analyses indi-
cate that risk of dying within 5 years has decreased by about 16%
since the early-mid 1990s, and this improvement is particularly
evident for leukaemias, for which the hazard ratio was 40% lower
for cases diagnosed in the late 90s or early 2000s. Similar
improvements in leukaemia survival over time have been reported
in the United States (Pulte et al, 2008), Canada (Ellison et al, 2007)
and France (Desandes et al, 2008).
Direct comparisons with published survival rates inter-
nationally need to be made with caution because of the different
methodologies used, such as the period or cohort method, and the
different time periods considered in the analyses. However this
study has demonstrated that the 5-year survival for all child-
hood cancers in Australia (79%) is similar to that reported
in many other developed areas of the world. Published inter-
national estimates range from 81% in 1996–2004 for the USA
(Anonymous, 2009), 81% among European children in 1995–2002
(Gatta et al, 2009), 80% between 1998–2002 in Slovenia
(Perme and Jereb, 2009), 80% in Italy between 1997–2001 (Zuccolo
et al, 2006), 75% in France between 1990–1999 (Desandes et al,
2008) and 82% in Canada between 1993–2003 (Ellison et al, 2007).
The lack of consistency in methodology when generating and
reporting international estimates of childhood-cancer survival
could lend support for a similar collaborative comparative study
equivalent to the CONCORD study for adults (Coleman et al,
2008).
Children who were diagnosed when less than 1 year of age
had a poorer prognosis for leukaemias (particularly lymphoid
Table 2 Relative survival for Australian children diagnosed with cancer by diagnostic group and stage, 1997–2006
a
Relative survival (95% confidence intervals)
Diagnostic group and stage N
b 1 year 5 year 20 year
II. Lymphomas
Stage I 259 98.4 (93.8–99.6) 96.3 (91.3–98.5) 96.5 (91.2–99.1)
Stage II 259 99.2 (94.6–99.9) 96.9 (91.9–98.9) 94.5 (88.4–97.7)
Stage III 321 90.6 (85.1–94.1) 84.3 (77.9–89.0) 80.1 (71.6–86.3)
Stage IV 138 92.8 (83.5–96.9) 86.1 (74.8–92.6) 85.0 (73.1–92.1)
Unknown 243 87.1 (79.7–91.9) 85.2 (77.4–90.5) 85.0 (77.0–90.6)
IV. Neuroblastoma
Stage I 104 98.7 (89.7–100.0) 95.6 (86.3–98.8) 96.0 (86.6–99.2)
Stage II 88 100.0 NA 90.9 (77.1–96.7) 91.3 (77.4–97.1)
Stage III 102 87.7 (74.4–94.4) 74.4 (59.1–84.7) 74.7 (59.3–85.1)
Stage IV 297 81.7 (75.5–86.5) 49.3 (42.0–56.2) 41.8 (33.8–49.7)
Unknown 59 91.1 (68.6–97.8) 91.2 (68.7–97.9) 86.9 (63.3–96.2)
VI. Renal tumours
Stage I 190 98.7 (90.3–99.9) 94.8 (86.4–98.1) 90.6 (80.3–95.8)
Stage II 135 100.0 NA 93.2 (84.1–97.2) 93.6 (84.5–97.7)
Stage III 165 97.4 (89.8–99.4) 92.3 (83.5–96.5) 91.3 (82.0–96.1)
Stage IV 122 91.2 (81.3–96.0) 75.1 (62.9–83.7) 73.7 (61.3–82.8)
Unknown 71 84.8 (69.2–92.9) 84.9 (69.2–93.0) 85.4 (69.6–93.6)
IXA. Rhabdomyosarcomas
Stages I/II 115 97.0 (88.2–99.3) 86.4 (75.3–92.7) 81.3 (66.5–90.2)
Stages III/IV 123 89.2 (77.6–95.0) 55.9 (42.5–67.4) 47.1 (34.8–58.6)
Unknown 105 91.2 (78.2–96.6) 68.9 (46.1–83.6) 66.3 (44.5–81.3)
Abbreviation: NA¼not applicable.
aIncludes all children who were diagnosed between January 1st 1983 and December 31st 2006, and were ‘at risk’ at some point between
1997 and 2006 (inclusive).
bN represents the total number ‘at risk’ between 1997 and 2006 (inclusive).
Survival for Australian childhood cancer
PD Baade et al
1666
British Journal of Cancer (2010) 103(11), 1663–1670 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sleukaemias) and tumours of the CNS, but had better prognosis for
neuroblastoma. These age effects were similar to those reported in
United States (Linabery and Ross, 2008), France (Desandes et al,
2008) and Canada (Ellison et al, 2007). It can be more difficult to
treat younger children because of a combination of differences in
the biological characteristics of their cancers along with their
ability to cope with the therapies that are usually applied. For
example, infants with leukaemia have been shown to be more
resistant to certain types of chemotherapy (Pieters et al, 2007) and
they can also be at higher risk of drug-induced toxicity due to
slower clearance rates of some chemotherapeutic agents (Koren
and Schechter, 2007). The use of traditional radiation therapy,
which is widely used in the treatment of older children with a
tumour of the central nervous system, is often deferred or avoided
in infants because of the possibility of significant adverse late
effects (Lafay-Cousin and Strother, 2009). The inverse relationship
between age at diagnosis and survival for children with
neuroblastoma has been reported previously, with patients less
than 1 years of age at diagnosis generally having smaller and less
aggressive tumours (van Noesel and Versteeg, 2004; Gutierrez et al,
2007; Haupt et al, 2010).
Overall survival was higher for children diagnosed in more
recent years, however, when analysed by diagnostic group, this
result was only statistically significant for leukaemias, with
some suggestion of an improvement for lymphomas. Improve-
ments in leukaemia survival over time have been reported
internationally (Brenner et al, 2007; Gatta et al, 2009) and have
been suggested to be most likely because of major progress in
treatment regimens (Brenner et al, 2007) and as a direct result
of collaborative clinical trials (Bond and Pritchard, 2006;
O’Leary et al, 2008). In Australia, all the main paediatric oncology
centres are publicly funded, which means there is no restriction
to treatment options according to whether a child’s family have
private health insurance. In addition, all Australian centres
have strong international collaborative connections with both
USA (Children’s Oncology Group) (O’Leary et al, 2008) and
Europe (SIOP – International Society of Paediatric Oncology)
(Pritchard-Jones, 2008).
As is the case for adult cancers, stage is a key prognostic factor
for childhood cancer. Children with cancers that were more
advanced at diagnosis generally experienced significantly poorer
survival, similar to findings in the French study (Desandes et al,
2008). The greatest variations in survival by stage in our data were
observed for neuroblastoma.
We also found that survival rates tended to stabilise within a few
years after diagnosis for most of the diagnostic groups regardless
of stage at diagnosis. This needs to be interpreted in the context of
the quality of life of longer-term survivors of childhood cancer,
which is often affected by complications such as subsequent
cancers, organ dysfunction (including cardiopulmonary, renal and
gastrointestinal), impaired growth and development, decreased
fertility and neurocognitive deficits, some of which will not
become apparent until many years later (Goldsby et al, 2006;
Landier and Bhatia, 2008). Long-term, multidisciplinary monitor-
ing of survivors is important in order to minimise where possible
the impact of these potential, adverse effects (Hewitt et al, 2003;
American Academy of Pediatrics Section on Hematology/Oncology
Children’s Oncology Group, 2009).
A strength of the Australian Paediatric Cancer Registry is its
complete population coverage, because of mandatory notification
of all cancers in Australia. However, even with the full population
coverage in Australia, the small numbers of some types of
childhood cancers diagnosed over the study period meant that
the corresponding confidence intervals were relatively wide. In
addition, the published values for death certificate only and
histological verification are indicative of the high data quality that
is achieved in Australian state and territory cancer registries
(Baade et al, 2010). The use of the period method for the analysis
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sof cancer survival is becoming more common and, following
validation in several studies, has been recommended as the
method of choice to monitor population-based survival (Brenner
et al, 2007).
These survival estimates provide quantitative data describing
the prognosis for Australian children diagnosed with cancer and
demonstrate consistency with survival outcomes reported inter-
nationally. They also provide a valid, high-quality baseline of
survival outcomes against which changes in survival can be
monitored over time. It is hoped that with further developments
in treatment protocols through large multicentre studies the
improvements in survival will continue.
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